Moderna, Inc. receives tender for the supply of its COVID-19 mRNA vaccine in the European Union -January 24, 2025 at 12:30 p.m.

Moderna, Inc. announced that it has won a tender for the supply of its COVID-19 mRNA vaccine to the European Union (EU), Norway and North Macedonia. Under the resulting agreement, 17 participating countries can have access to Moderna's COVID-19 mRNA vaccine for up to four years. Under the agreement, Moderna can supply its COVID-19 vaccine in multiple forms, including pre-filled syringes.

This is the preferred product presentation for healthcare providers because it can decrease the risk of administration errors and save time, which can ultimately improve the effectiveness of vaccination campaigns. In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine, Spikevax, targeting the JN.1 variant of SARS-CoV-2, for immunization active to prevent COVID-19 caused by SARS-CoV-2 in people aged six months and older.